ReviewHematology. American Society of Hematology. Education Program2010
Sickle-cell trait: novel clinical significance.
Review in Hematology. American Society of Hematology. Education Program, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Phenome- and laboratory-wide meta-analyses of sickle cell trait reveal multi-system disease associations.American journal of human genetics · 2026Pooled it
- KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors.Transplantation · 2017Guideline
- Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.The Cochrane database of systematic reviews · 2015Pooled it
- Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans.JAMA · 2014Pooled it
- A machine-learning capillary electrophoresis-based pattern to identify suspected sickle cell trait and α-thalassemia co-inheritance.Advances in laboratory medicine · 2026Article
- Newborns with sickle cell trait have distinct peripheral blood molecular signatures across the first week of life.Blood. Red cells & iron · 2026Article
- Is sickle cell trait truly benign? A case-control study of physical and mental health outcomes from the sickle cell belt of Eastern India.Journal of community genetics · 2026Article
- The role of hemoglobin F in sickle cell disease complications: a descriptive secondary analysis.Blood vessels, thrombosis & hemostasis · 2026Article
- Article
- Sickle cell trait, APOL1 risk allele status and chronic kidney disease among ART-experienced adults living with HIV in northern Nigeria.International journal of STD & AIDS · 2025Article
- Genotype-dependent albuminuria in adult sickle cell disease in Kinshasa.Annals of hematology · 2025Article
- Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model.Blood advances · 2025Article
- Coexisting systemic lupus erythematosus with lupus nephritis and sickle cell trait: a case report of rare combination.Annals of medicine and surgery (2012) · 2025Article
- Vaso-Occlusive Crises in Sickle Cell Trait Patients With Blood Loss Anemia: A Report of Two Cases.Cureus · 2024Article
- Management of the Sickle Cell Trait: An Opinion by Expert Panel Members.Journal of clinical medicine · 2023Review
- Differences between reference intervals of blood counts of Brazilian adults with and without sickle cell trait according to laboratory tests from the National Health Survey.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2023Article
- Etiology of Persistent Microalbuminuria in Nigeria (P_MICRO study): protocol and study design.BMC infectious diseases · 2022Article
- Article
- Bendamustine-induced nephrogenic diabetes insipidus - A case report.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2022Article
- Health services use by children identified as heterozygous hemoglobinopathy mutation carriers via newborn screening.BMC pediatrics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
There is a long-standing controversy in the literature as to whether sickle-cell trait (SCT) should be viewed as a benign carrier state or as an intermediate disease phenotype. Because SCT is routinely detected by neonatal screening for sickle-cell disease, it becomes imperative that consensus on this issue be achieved in order to provide the best medical advice to affected individuals. The issue of selective screening in the post-neonatal period was thrust into the limelight recently by the National Collegiate Athletic Association's recommendation that its member colleges and universities test student-athletes to confirm their carrier status if not already known. The stated goal of this recommendation was to prevent exercise-related sudden death in athletes with SCT. We review some of the reported complications of SCT for which new information has emerged, focusing particularly on venous thromboembolism and renal manifestations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.